About
Immunotherapies
Areas of Focus
Categories
Biologics & BiopharmaceuticalBiotech
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
6
As Collaborator
0
Total Enrollment
1,094
By Phase
PHASE2: 4PHASE1/PHASE2: 1PHASE3: 1
By Status
COMPLETED: 5ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT04884256Lead Sponsor
Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula
PHASE2Completed
88 participants
Started: Dec 21, 2023 · Completed: May 30, 2025
NCT05372991Lead Sponsor
Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop
PHASE1/PHASE2Completed
84 participants
Started: Jul 20, 2022 · Completed: Jan 20, 2023
NCT05456425Lead Sponsor
A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium
PHASE3Active, not recruiting
660 participants
Started: Jun 30, 2022 · Completed: Dec 31, 2027
NCT05261386Lead Sponsor
Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction
PHASE2Completed
95 participants
Started: Mar 4, 2022 · Completed: Mar 29, 2023
NCT04884243Lead Sponsor
Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction
PHASE2Completed
92 participants
Started: Sep 5, 2021 · Completed: Aug 17, 2023
Locations (1)
Headquarters
Berkeley, CA, United States
Map
Loading map...